Nicole Lambert - Oct 1, 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role: Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.
Signature: By: Nathan A. Smith For: Nicole Lambert
Stock symbol: MYGN
Transactions as of: Oct 1, 2021
Transactions value $: -$44,835
Form type: 4
Date filed: 10/4/2021, 04:16 PM
Previous filing: Sep 27, 2021
Next filing: Oct 12, 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MYGN	Common Stock	Sale	-$44.8K	-1.42K	-0.8%	$31.57	177K	Oct 1, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.01, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.01, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.